BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

CureVac collaborates with Yale for mRNA-based pulmonary therapeutics

August 19, 2019 | News

The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases.



CureVac AG, a fully integrated Germany based biopharmaceutical company pioneering the field of mRNA-based drugs, announced that it has entered into a Collaborative Research Agreement (CRA) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.

The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases. Under terms of the CRA, the Yale University team, led by Geoff Chupp, MD, will perform discovery research on targets related to pulmonary diseases and present therapeutic candidates to CureVac for preclinical and subsequent clinical development. CureVac will provide all funding for the discovery research and retains the option to acquire any rights regarding the candidates.

To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp's dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.